INVESTABOT
Equity Research
XNAS · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
Incyte Genomics (INCY) had 1 Form 144 pre-sale notice filed on 2026-09-15. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one…
Incyte Genomics (INCY) had 1 Form 144 pre-sale notice filed on 2026-08-19. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one…
Incyte Genomics (INCY) had 1 Form 144 pre-sale notice filed on 2026-08-12. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one…
Incyte Genomics (INCY) had 1 Form 144 pre-sale notice filed on 2026-08-03. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one…
Incyte Genomics (INCY) had 2 Form 144 pre-sale notices filed on 2026-08-05. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one…
Incyte Genomics (INCY) had 2 Form 144 pre-sale notices filed on 2026-07-31. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one…
Incyte Genomics (INCY) had 1 Form 144 pre-sale notice filed on 2026-07-16. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one…
Incyte Genomics (INCY) had 1 Form 144 pre-sale notice filed on 2026-07-16. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one…
Incyte Genomics (INCY) had 1 Form 144 pre-sale notice filed on 2026-07-15. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one…
Incyte Genomics (INCY) had 1 Form 144 pre-sale notice filed on 2026-06-04. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one…
Incyte Genomics (INCY) had 1 Form 144 pre-sale notice filed on 2026-05-26. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one…
Incyte Genomics (INCY) had 1 Form 144 pre-sale notice filed on 2026-05-19. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one…
open-market Form 4 only - grants, exercises, tax withholding excluded
0 buyers - 5 unique sellers · Institutional activity: not available - insufficient comparable institutions for the latest complete quarter.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| September 30, 2026 | Harrigan Edmund | — | GRANT | 206 | $121 | ~$25K |
| September 30, 2026 | Clancy Paul J | — | GRANT | 203 | $121 | ~$25K |
| September 30, 2026 | Baker Bros. Advisors Lp | — | GRANT | 322 | — | — |
| September 22, 2026 | Gardner David H | EVP, Chief Strategy Officer | TAX_WITHHOLD | -920 | $127 | ~$0.1M |
| September 15, 2026 | Cagnoni Pablo J | President, Global Head of R&D | OPTION_EXERCISE | -9,233 | — | — |
| September 15, 2026 | Cagnoni Pablo J | President, Global Head of R&D | OPTION_EXERCISE | -6,477 | — | — |
| September 15, 2026 | Cagnoni Pablo J | President, Global Head of R&D | OPTION_EXERCISE | -4,551 | — | — |
| September 15, 2026 | Cagnoni Pablo J | President, Global Head of R&D | OPTION_EXERCISE | -2,957 | — | — |
| September 15, 2026 | Cagnoni Pablo J | President, Global Head of R&D | SELL | -13,985 | $120 | ~$1.7M |
| September 15, 2026 | Cagnoni Pablo J | President, Global Head of R&D | SELL | -9,233 | $121 | ~$1.1M |
| September 15, 2026 | Cagnoni Pablo J | President, Global Head of R&D | OPTION_EXERCISE | 9,233 | $72 | ~$0.7M |
| September 15, 2026 | Cagnoni Pablo J | President, Global Head of R&D | OPTION_EXERCISE | 6,477 | $64 | ~$0.4M |
| September 15, 2026 | Cagnoni Pablo J | President, Global Head of R&D | OPTION_EXERCISE | 4,551 | $61 | ~$0.3M |
| September 15, 2026 | Cagnoni Pablo J | President, Global Head of R&D | OPTION_EXERCISE | 2,957 | $62 | ~$0.2M |
| August 25, 2026 | Basi Ramitpal K | EVP, Human Resources | TAX_WITHHOLD | -504 | $130 | ~$65K |
| August 19, 2026 | Cagnoni Pablo J | President, Global Head of R&D | SELL | -10,801 | $126 | ~$1.4M |
| August 12, 2026 | Cagnoni Pablo J | President, Global Head of R&D | SELL | -10,803 | $120 | ~$1.3M |
| August 5, 2026 | Cagnoni Pablo J | President, Global Head of R&D | SELL | -10,640 | $123 | ~$1.3M |
| August 5, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | OPTION_EXERCISE | 2,207 | $106 | ~$0.2M |
| August 5, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | SELL | -2,207 | $124 | ~$0.3M |
| Date | Filer | Relationship | Est. shares | Filing |
|---|---|---|---|---|
| September 15, 2026 | Pablo Cagnoni | — | 23,218 | SEC |
| August 19, 2026 | Pablo Cagnoni | — | 10,801 | SEC |
| August 12, 2026 | Pablo Cagnoni | — | 10,803 | SEC |
| August 5, 2026 | Pablo Cagnoni | — | 10,640 | SEC |
| August 5, 2026 | Patrick A Mayes | — | 2,207 | SEC |
| August 3, 2026 | Patrick A Mayes | — | 6,055 | SEC |
| July 31, 2026 | Pablo Cagnoni | — | 15,888 | SEC |
| July 31, 2026 | Patrick A Mayes | — | 41,899 | SEC |
| July 16, 2026 | Mohamed Issa | — | 1,093 | SEC |
| July 16, 2026 | Steven Stein | — | 1,877 | SEC |
| Date | Insider | Title | Relationship | Shares | Filing |
|---|---|---|---|---|---|
| May 6, 2026 | — | — | — | — | SEC |